Facilitating Access to Medicine for Developing and Least Developed Countries by WTO, with Emphasis on Latest Developments in TRIPS Agreement

Today, with the rise of various diseases, the lives of human societies are more and more endangered. Therefore, the pharmaceutical industry is one of the most important industries to be supported in order to maintain the incentive to invent new drugs for dangerous and emerging diseases, as well as the incentive to produce widespread pharmaceuticals for inventors and investment companies in the industry. Against the undeniable advantages of protecting inventors and drug manufacturers, this support can lead to the emergence of some countries, especially developing and least developed countries, with serious threats to public health and the inability to access proprietary drugs, they face. Which of these two options is preferred over the other? Protecting the pharmaceutical industry or protecting public health against threats? Accordingly, the paper examines the World Trade Organization's Facilitation of Drug Access for Developing Countries and least developed countries with emphasis on developments in the Trips Treaty. In short, along with the World Health Organization, whose role is to help maintain health, the World Trade Organization has tried to incorporate some of the acts in the trips agreement as well as its "reform", while maintaining its fundamental principles, such as freedom of trade and the principle of non-discrimination, to protect public health from threats, in order to prevent the conflict between the two.